TRANSCEND CLL004: Might CAR T-cell therapy become standard-of-care for CLL? 

During the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the Lymphoma Hub spoke with Tanya Siddiqi, City of Hope Comprehensive Cancer Center, Duarte, US. We asked, Might chimeric antigen (CAR) T-cell therapy become a standard-of-care for chronic lymphocytic leukemia (CLL)?
Patients with CLL who progress on novel Bruton's tyrosine kinase inhibitors and venetoclax treatment have a high unmet need for further treatment options. Here, Siddiqi discusses the TRANSCEND CLL 004 study (NCT03331198), highlighting the clinical benefits of axicabtagene ciloleucel and the potential for this CAR T-cell therapy as standard-of-care for patients with CLL who have relapsed after Bruton's tyrosine kinase inhibitor or venetoclax therapy.
Visit www.lymphomahub.com for more information on this topic.